Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.

ABSTRACT: Cancer immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized oncology. However, only a limited number of patients benefit from immunotherapy, and some cancers that initially respond to immunotherapy can ultimately relapse and progress. Thus, some studies have investigated combining immunotherapy with other therapies to overcome resistance to monotherapy. Recently, multiple preclinical and clinical studies have shown that tumor vasculature is a determinant of whether immunotherapy will elicit an antitumor response; thus, vascular targeting may be a promising strategy to improve cancer immunotherapy outcomes. A successful antitumor immune response requires an intact "Cancer-Immunity Cycle," including T cell priming and activation, immune cell recruitment, and recogni

SUBMITTER: Li SJ 

PROVIDER: S-EPMC8441058 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature